Clinical trials: COPD Exacerbation
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
COPD Patients
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- RISE (NCT02157935)
- Testing
- Symbicort, Formoterol turbohaler
- Where
- 371 sites in United States, Argentina and 9 more
- Volunteers
- 2,026 people
- Sponsor
- AstraZeneca
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.
- Trial name
- TERRANOVA (NCT02155660)
- Testing
- Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 2,255 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
COPD, COPD Exacerbation
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders
- Trial name
- NCT01443845
- Testing
- Roflumilast
- Where
- 338 sites in United States, Argentina and 15 more
- Volunteers
- 2,354 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.
- Trial name
- NCT01782326
- Testing
- QVA149, Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
- Where
- 499 sites in Argentina, Austria and 41 more
- Volunteers
- 3,362 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.
The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in…
- Trial name
- NCT02296138
- Testing
- olodaterol, tiotropium
- Where
- 818 sites in United States, Argentina and 49 more
- Volunteers
- 7,903 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Exacerbation Study
This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks
- Trial name
- INVIGORATE (NCT00845728)
- Testing
- Indacaterol 150 µg, Tiotropium
- Where
- 423 sites in Argentina, Australia and 38 more
- Volunteers
- 3,439 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD
Nasal High Flow Therapy 30 Day Readmission Study
The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy…
- Trial name
- N3ADS (NCT02552732)
- Testing
- NHF with or without Oxygen
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 29 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- COURSE (NCT04039113)
- Testing
- Tezepelumab
- Where
- 91 sites in United States, Canada and 8 more
- Volunteers
- 337 people
- Sponsor
- AstraZeneca